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ÖZET
Ateroskleroz artan bir şekilde dammar sisteminin immune 
system aracılı bir oluşumu olarak algılanmaktadır. Otoan-
tikorlar, otoantijenler, yangı artırıcı sitokinler ve enfeksiyöz 
etkenler bu oluşumda rol alabilir. Ototimmunite bağlantılı 
kalp-damar hastalıkları ve damar sertliği önemli klinik so-
runlardır. Otoimmun romatizmal hastalıklarda hızlanmış 
damar sertliği gelişmesinin nedeni açık değildir. Bazı oto-
immunite ilişkili kalp-damar sorunları damar sertliğinden 
ziyade tromboz ile ilişkilidir. Artan riskin mekanizmaları 
net  olarak  açıklanmamakla  birlikte,  geleneksel  olan  ve 
olmayan risk faktörlerinin - yangı da içlerinde olarak – bir 
kombinasyonu önemli gözükmektedir. Otoimmun romatiz-
mal hastalıkların hızlanmış damar sertleşmesi ve belirtile-
ri ile birlikte olup olmadığı konusunda yeni araştırmalara 
gereksinim vardır. Klin Den Ar Derg 2010; 1(3): 232-234
Anahtar kelimeler: Damar sertliği, otoimmun hastalıklar, 
mekanizmalar
ABSTRACT
Atherosclerosis  is  increasingly  considered  an  immune 
system-mediated process of the vascular system. Autoan-
tibodies,  autoantigens,  pro-inflammatory  cytokines  and 
infectious agents play a role in that process. Autoimmuni-
ty-related cardiovascular disease and atherosclerosis are 
important clinical problems. The reason for accelerated 
atherosclerosis  in  patients  with  autoimmune  rheumatic 
diseases remains unclear. Some cases of autoimmunity-
related cardiovascular disease may be more related to 
thrombosis than atherosclerosis. Although, mechanisms 
causing the increased risk are not precisely clarified, a 
combination of traditional and nontraditional risk factors, 
including inflammation appears to be of importance. Fur-
ther studies are needed to determine whether these au-
toimmune rheumatic diseases are also associated with 
accelerated atherosclerosis and its manifestations. J Clin 
Exp Invest 2010; 1(3): 232-234
Key words: Atherosclerosis, autoimmune rheumatic dis-
eases, mechanisms
INTRODUCTION
The mechanisms for the assumed accelerated athero-
sclerosis in autoimmune rheumatic diseases such as 
systemic lupus erythematosus, rheumatoid arthritis, 
systemic sclerosis include the classical risk factors, 
but may also be due to chronic inflammatory pro-
cesses and immune dysregulation.1,2 This phenom-
enon can be attributed to the traditional risk factors 
for atherosclerosis and use of specific drugs, such as 
corticosteroids, but also may be the result of other 
autoimmune and inflammatory mechanisms that are 
aggravated  in  autoimmune  rheumatic  diseases.3,4 
Several autoantibodies are associated with athero-
sclerosis and its manifestations in humans. The anti-
body levels were higher in those patient groups than 
in control subjects.5,6
Accelerated atherosclerosis in rheumatoid 
arthritis
Several types of cardiac involvement can occur in 
rheumatoid arthritis (RA). RA itself seems to rep-
resent a significant risk factor for development of 
early  atherosclerosis  and  cardiovascular  diseases 
(CVD).7-9  RA  treatment  and  lifestyle  of  RA  pa-
tients may favor physical inactivity, hypertension, 
diabetes mellitus, and obesity, but there is no clear M. Cojocaru et al. Atherosclerosis in autoimmunity 233
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evidence that these factors are implicated in acceler-
ated atherosclerosis in RA.10-12 Despite the fact that 
different factors could alter endothelium homeosta-
sis, prevalent data support the view that abnormal 
endothelial function in RA is essentially linked to 
inflammation.13, 14
Accelerated atherosclerosis in SLE
Although  atherosclerosis  develops  early  in  the 
course of the disease, older age at diagnosis seems 
to be the major determinant of atherosclerosis in 
SLE.15 Among the nontraditional risk factors, cu-
mulative dosage and/or longer duration of corticos-
teroid therapy and longer duration of disease seem 
to be the major predictors of atherosclerosis in SLE 
studies.16 The evaluation of risk factors for clinical 
atherosclerosis is difficult in SLE, since there are 
few observed cardiovascular events because of low 
prevalence of the disease.17 Whether premature ath-
erosclerosis is a general feature of autoimmune dis-
eases such as SLE or only affects a subgroup of pa-
tients whereas others do not have an increased risk 
remains to be demonstrated.18
Accelerated atherosclerosis in antiphospholipid 
syndrome
The  pathogenesis  of  accelerated  atherosclerosis 
in APS may be a result of an interaction between 
traditional and nontraditional risk factors.19 Throm-
bophilia may be associated with premature athero-
sclerosis, and accelerated atherosclerosis was sug-
gested as an additional clinical feature of APS.20 
This pathological process may be mediated by the 
direct  proinflammatory  and  procoagulant  activity 
that  anti-phospholipid  antibodies  (aPLs)  exert  on 
endothelial cells or indirectly, via the inflammatory 
immune mechanisms that have been implicated in 
autoantibody-mediated thrombosis.21 Further stud-
ies  are  needed  to  determine  whether  atheroscle-
rotic plaques in autoimmune disease have special 
features or whether systemic factors such as aPLs 
trigger atherothrombosis more easly than in normal 
atherosclerosis.22
Accelerated atherosclerosis in systemic sclerosis
Systemic sclerosis affects the microcirculation and 
injures the endothelium, leading eventually to vessel 
occlusion and tissue anoxia.23 In addition, systemic 
sclerosis significantly accelerates the sufferance of 
the vessel wall of the macrocirculation, increasing 
the risk of vascular occlusive diseases. Extend of 
enhanced  atherosclerosis  in  systemic  sclerosis  is 
not yet clear, because fewer studies compared with 
those of RA, SLE, and APS.24
Primary systemic vasculitis and accelerated 
atherosclerosis
Many similarities exist between atherosclerosis and 
primary systemic vasculitis with respect to the ini-
tial localization, the role of multiple causal factors 
and  pathogenetic  mechanisms,  and  some  clinical 
manifestations and possible future treatment strat-
egies.25 Vessel intima is the site at which inflamma-
tion develops in atherosclerosis and in most types of 
primary systemic vasculitis.26 Vasculitis may trigger 
or favor not only inflammatory but also immune re-
actions associated with atherogenesis, for example, 
increasing the expression of autoantigens on acti-
vated endothelial cells.27,28
Atherosclerosis in Sjögren’s syndrome
Cardiac involvement is very rare among patients 
having Sjögren’s syndrome.3 Currently there is no 
available data suggesting that this common autoim-
mune condition is associated with enhanced athero-
sclerosis. The data suggest that further studies are 
indicated to determine the risk of atherosclerosis 
among patients with Sjögren’s syndrome.5,6
Conclusions
Enhanced and premature atherosclerosis is a fea-
ture of some autoimmune rheumatic diseases and a 
possible feature of others because of inflammation 
and more specific immune mechanisms. The risk of 
cardiovascular disease is very high in SLE and also 
increased in RA and most likely to a varying degree 
in  other  autoimmune  disease.  However,  it  is  not 
clearly established that the increased risk is present 
in most if not all patients, or only affects a smaller 
subgroup of patients.
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